HIV JournalView

No Excess Death Among HIV-Infected People -- as Long as CD4+ Cell Counts Are Kept Close to Normal (March 15, 2013)
A new study gives us the most conclusive evidence to date that HIV-positive people who take their meds and keep their CD4 count above 500 are just as healthy overall as HIV-negative people.
In HIV JournalView, from TheBodyPRO.com
Dangers of Smoking Greatly Enhanced for HIV-Infected Patients, Study Finds (February 21, 2013)
A recently published study from a national cohort of HIV-infected Danes supplies a bunch of new facts that you can use to scare -- er, counsel -- your patients afflicted with tobaccoism.
In HIV JournalView, from TheBodyPRO.com
Top 10 HIV Clinical Developments of 2012 (December 2012)
In HIV JournalView, from TheBodyPRO.com
HIV JournalView: October/November 2012 (November 27, 2012)
David Alain Wohl, M.D., looks at new findings regarding racial disparities in HIV care, predicting hospital readmissions, sexual transmission of HCV, treatment of diabetes, and more accurate/efficient ways to measure and predict adherence.
In HIV JournalView, from TheBodyPRO.com
HIV JournalView: September 2012 (October 15, 2012)
David Alain Wohl, M.D., explores recently published findings regarding access to HIV care in the U.S., the impact of pain on clinic no-shows, links between atazanavir and gall/kidney stones, anal sex and HIV among women, and the limits of echocardiography.
In HIV JournalView, from TheBodyPRO.com
HIV JournalView (October/November 2007)
Breaking research on malignancies, metabolic complications, darunavir resistance, sperm washing and more -- concise analysis from David Wohl, M.D.
In HIV JournalView, from TheBodyPRO.com
HIV JournalView (September 2007)
Among other reviews this month, David Wohl, M.D., looks at the latest studies on entecavir and HIV drug resistance and examines how saturated fat intake contributes to HIV-associated hypertriglyceridemia.
In HIV JournalView, from TheBodyPRO.com
HIV JournalView (July 2007)
Among other stories this month, Graeme Moyle, M.D., reviews the potential for shifting HIV tropism and what this means to the use of CCR5 antagonists.
In HIV JournalView, from TheBodyPRO.com
Top 10 HIV Medical Stories of 2006 (February 2007)
It's one of the most insightful, entertaining, informative HIV research recaps you'll read this year: The Body PRO's David Wohl, M.D., presents an end-of-year review of the developments that made the biggest waves among HIV health care professionals in 2006. If you're looking for an easy-to-digest recap of the most critical news in HIV over the last calendar year, this is the article to read.
In HIV JournalView, from TheBodyPRO.com
HIV JournalView (September/October 2006)
Pablo Tebas, M.D., analyzes recently published research on: the utility (or lack thereof) of viral load tests in predicting the rate of CD4+ cell decline; the tendency for HIV-infected patients to have a poorer prognosis when diagnosed with lung cancer than their HIV-uninfected counterparts; the potential for drug interactions between enfuvirtide and ritonavir-boosted tipranavir; and the high prevalence of human papillomavirus infection among sexually active men.
To read PDF, click here.
In HIV JournalView, from TheBodyPRO.com
HIV JournalView (May/June 2006)
David Wohl, M.D., examines published research on the quantifiable benefits of HIV care; predicting response to atazanavir/ritonavir; the need for baseline resistance testing; widespread belief in HIV conspiracy theories; adherence and risk-reduction interventions; and recent patterns in body fat changes among HAART patients.
To read PDF, click here.
In HIV JournalView, from TheBodyPRO.com
HIV JournalView (February/March 2006)
David Wohl, M.D., analyzes a head-to-head comparison of tenofovir + emtricitabine + efavirenz versus zidovudine/lamivudine + efavirenz in treatment-naive patients; the relationship between antiretroviral class, adherence and resistance; the successes and limitations of HAART in the developing world; and mixed news on investigational enfuvirtide administrations (good news on needle-free administration; bad news on once-daily dosing).
To read PDF, click here.
In HIV JournalView, from TheBodyPRO.com
Top 10 Research Publications in HIV Care of 2005 (January 2006)
Thousands of HIV-related studies were published in 2005, but only a handful heralded fundamental changes in the way we approach HIV screening and treatment; David Wohl, M.D., recaps these critical studies and explains their significance in this issue of HIV JournalView.
To read PDF, click here.
From TheBodyPRO.com
HIV JournalView (December 2005)
Mark Holodniy, M.D., discusses recently published studies on partial HIV treatment interruption, lopinavir/ritonavir monotherapy, hyperlipidemia management strategies, coadministration of didanosine + tenofovir, the success of treatment access programs in the developing world, and the protective benefits of male circumcision.
To read PDF, click here.
In HIV JournalView, from TheBodyPRO.com
HIV JournalView (November 2005)
Margaret Hoffman-Terry, M.D., analyses the findings of recently published studies on the relationship (or lack thereof) between lipoatrophy and lipohypertrophy, shedding of nevirapine-resistant virus in breast milk, neuropsychiatric impairment in HIV/hepatitis C-coinfected patients, and the importance of using CD4+ cell percentage in treatment initiation decisions.
To read PDF, click here.
In HIV JournalView, from TheBodyPRO.com
HIV JournalView (September 2005)
David Wohl, M.D., reviews recently published research on the need (or lack thereof) to switch regimens in patients with low-level viremia, a dementia test for resource-poor areas, the growing epidemic of obesity among HIV-infected patients, the link between insulin resistance and NRTIs (not PIs!), and a final word on the whole valproic acid/"HIV cure" kerfuffle.
To read PDF, click here.
In HIV JournalView, from TheBodyPRO.com
HIV JournalView (July/August 2005)
David Wohl, M.D., reviews many newly published studies, including research on the role of HAART in hypertension, the interaction between efavirenz (EFV, Sustiva, Stocrin) and statins, the best way to manage dyslipidemia in HAART patients, and several new approaches to HIV therapeutics.
To read PDF, click here.
In HIV JournalView, from TheBodyPRO.com
HIV JournalView (May/June 2005)
Margaret Hoffman-Terry, M.D., examines recent studies on a range of HIV-related health problems, including bone and joint problems, the long-term health risks of tenofovir (TDF, Viread), the neurological effects of efavirenz (EFV, Sustiva, Stocrin) and new insight into the treatment of people who are coinfected with HIV and hepatitis C.
To read PDF, click here.
In HIV JournalView, from TheBodyPRO.com
HIV JournalView (April 2005)
Mark Holodniy, M.D., analyzes recently published research on poly-L-lactic acid for facial wasting, resistance testing, interactions between antiretrovirals and natural health products, and several other topical issues in HIV disease management.
To read PDF, click here.
In HIV JournalView, from TheBodyPRO.com
HIV JournalView (February/March 2005)
David Wohl, M.D., assesses the significance of recent research on predictors of HIV drug resistance, cost-effectiveness of HIV screening, contraindication of fosamprenavir lopinavir/ritonavir, incidence of NNRTI-related rash and an update on metabolic complications.
To read PDF, click here.
In HIV JournalView, from TheBodyPRO.com
Top 10 Research Reports of 2004 (January 2005)
David Wohl, M.D., reviews the top 10 published research reports of 2004.
To read PDF, click here.
In HIV JournalView, from TheBodyPRO.com

1 | 2 Next >